GSK

Strong performance in its long-acting HIV preventable has helped GlaxoSmithKline to raise its profit forecasts

Companies October 31, 2025

GSK’s Q3 results buoyed by long-acting HIV jab

Strong performance in its long-acting HIV preventable has helped GlaxoSmithKline to raise its profit forecasts, with five new long-acting product launches now expected by 2030….

GSK

GSK’s Q3 results buoyed by long-acting HIV jab

Receive our weekly briefing on AI in global health

From our team of writers around the world